arrow
J

Jason Fangusaro

northwestern university
H指数:44
被引数:7,804

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13

PD1和免疫通路活性在恶性儿科中枢神经系统(CNS)肿瘤中的最新分析:一项儿科脑肿瘤协作组(PBTC)研究,PBTC-N13

2025-11-010
OAAI
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 2: challenges, opportunities, and recommendations for clinical translation

人工智能在儿科神经肿瘤学反应评估中的应用(AI-RAPNO),第二部分:临床转化中的挑战、机遇与建议

2025-10-270
PRE
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 1: review of the current state of the art

人工智能在儿科神经肿瘤学反应评估中的应用(AI-RAPNO),第一部分:当前技术状态的综述

2025-10-270
PRE
Diffuse leptomeningeal glioneuronal tumor (DLGNT): a comprehensive clinical and molecular analysis

弥漫性软脑膜胶质神经元肿瘤(DLGNT):一项全面的临床与分子分析

2025-08-110
OAAI
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report

神经肿瘤学反应评估(RANO)2009–2025:广泛范围与实施——进展报告

2025-06-012
PRE
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4

一项关于selumetinib治疗复发性/进展性儿童低级别胶质瘤的PBTC二期研究:Strata 2、5和6,以及Strata 1、3和4的长期结局。

2025-04-170
PRE
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions
2024-10-230
PRE
POOR RESPONSE TO MEKI RE-INITIATION IN PEDIATRIC LOW-GRADE GLIOMA AFTER TREATMENT DISCONTINUATION. A PLGG TASKFORCE STUDY
2024-06-180
OAAI
REPORT ON PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC)-029B, A PROSPECTIVE PHASE 2 CLINICAL TRIAL OF SELUMETINIB IN TREATING YOUNG PATIENTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA: NEW RESULTS ON STRATA 2, 5, AND 6 WITH UPDATED LONG-TERM SURVIVAL OUTCOMES ON STRATA 1, 3, AND 4
2024-06-180
OAAI
PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC)-056: A PHASE 1 STUDY OF THE ADAM-10 INHIBITOR, INCB007839, IN CHILDREN WITH RECURRENT/PROGRESSIVE HIGH-GRADE GLIOMAS TO TARGET MICROENVIRONMENTAL NEUROLOGIN-3
2024-06-180
OAAI
PHASE 1 STUDY OF THE CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M (SOTIGALIMAB) IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH RECURRENT OR PROGRESSIVE CNS TUMORS AND NEWLY DIAGNOSED BRAIN STEM GLIOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC-051; NCT03389802)
2024-06-180
OAAI
PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH CHILDHOOD BRAIN CANCER: INTERIM ANALYSIS OF THE GCC1949 STUDY (NCT04049669)
2024-06-180
OAAI
A PHASE III STUDY COMPARING TWO CARBOPLATIN CONTAINING REGIMENS FOR CHILDREN AND YOUNG ADULTS WITH PREVIOUSLY UNTREATED LOW-GRADE GLIOMA
2024-06-180
OAAI